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ABSTRACT 
Nanoparticle (NP) assisted diagnosis and drug delivery for antitumor applications have been 
widely investigated in the past few decades. To date, some of them have been approved for 
clinical applications and many more of them are under clinical trials. Although some progress 
has been achieved, it is still necessary to explore novel materials for antitumor applications. 
The work summarized in this thesis focused on organic NPs, and evaluated engineered 
polymer NPs and protein-lipid NPs as antitumor drug delivery systems in vitro. And a 
multifunctional fluorinated NP system was also assessed as theranostic (the combination of 
therapy and diagnosis) platform. 
In paper I, two types of 2,2 bis(hydroxymethyl) propionic acid (bis-MPA) based dendritic-
linear (DL) polymers were synthesized. One type has the hyperbranched (HB) dendritic 
structure while the other has dendrons (perfectly branched structures). HBDL and DL 
materials were compared as drug delivery systems in respect to their synthesis difficulty, 
quality of micelle formation and efficiency in drug delivery. It was found that HBDL can be 
synthesized in large scales and drug loaded HBDL tended to have stronger efficacy compared 
to DL, therefore it is a promising alterative to DL in anticancer drug delivery. Further, in 
paper II, a detailed study regarding the uptake profile of a bis-MPA based hyperbranched 
copolymer micelle was conducted. The NP consisted of a Boltorn-H30 core (hyperbranched 
polyester) and PEG10k hydrophilic tails. It was found that the hyperbranched NP can be 
internalized into breast cancer cells via clathrin-dependent and macropinocytosis-mediated 
pathway through a time, concentration and energy dependent process. In paper III, 
fluorinated copolymers micelles were synthesized and evaluated as theranostic system, which 
has both diagnostic and therapeutic functions. The consequent micelles were able to load and 
release doxorubicin (DOX) and demonstrated similar efficacy compared to free (non-
formulated) DOX. Also these NPs could generate a detectable signal for 19F-MRI in vitro. In 
paper IV, unimolecular NPs were developed from polyester based hyperbranched dendritic-
linear polymers (HBDLPs). Such micelles were homogenous and did not have critical micelle 
concentration (CMC). And they were able to load DOX and delivery the drug into breast 
cancer cells. One HBDLP based NP containing a fluorinated polymer fragment was also 
synthesized to prove that these unimolecular systems are potentially useful as theranostic 
platforms. In paper V, histamine functionalized copolymer micelles were developed in order 
to introduce pH responsive property to NPs and achieve endo-lysosomal escape. These NPs 
were non-toxic and capable of loading and release DOX. Drug loaded NPs exhibited 
significant enhanced inhibition of mitochondria function in breast cancer cells during short 
periods (12 h) compared to free DOX. Although the expected pH responsive behaviour was 
not observed for the in vitro drug release model, NPs with histamine functionalization 
demonstrated partly endo-lysosomal escape property, in particular for those with 50% 
histamine modification. Intracellular tracking of NPs revealed that they could escape from 
endo-lysosomes and relocate DOX into mitochondria and the nuclei. In paper VI, lipoprotein 
like NP systems were developed by incorporating Saposin A, phospholipids and selected 
hydrophobic cargos. Such systems were shown to have promise as drug delivery platforms 
and to serve as NP based vaccine stabilizers.  
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1 INTRODUCTION 
 
1.1 BREAST CANCER AND THE MODULAR DRUG 
Breast cancer is one of the most prevalent malignant diseases in women in Western countries. 
Although the death rate of breast cancer from the primary tumor is not the highest compared 
to other type of carcinomas, its metastases often lead to other deadly cancers.1 As a result, 
early detection and treatment of breast cancer is imperative and worthy of study. Driven by 
this goal, nanotechnology has played an irreplaceable role in establishing novel diagnostic 
and therapeutic approaches. In 2005, Abraxane (albumin-entrapped paclitaxel) was approved 
by the Food and Drug Administration (FDA) as the first nanomedicine for metastatic breast 
cancer treatment, and this drug has demonstrated improved efficacy compared to pure 
paclitaxel.2,3 In addition, nanoparticle (NP)-assisted imaging and detection of breast cancer 
has also been reported.4,5 For instance, iron oxide NPs (IONPs) conjugated with recombinant 
amino-terminal fragment of urokinase-type plasminogen activator could act as a contrast 
agent of magnetic resonance imaging (MRI) for breast cancer diagnosis in vivo.6 
 
Figure 1. Chemical structures of doxorubicin and daunorubicin. 
Anthracycline antitumor drugs, including both doxorubicin (DOX) and daunorubicin (Figure 
1), can intercalate into the DNA of rapidly growing cells like cancer cells and can inhibit their 
proliferation.7 However, the administration of anthracylines can induce severe cardiotoxicity 
among other side-effects,8 and this limits their clinical usefulness. Unlike other common 
chemotherapeutics such as paclitaxel and gemcitabine, the intrinsic fluorescent properties of 
the anthracyclines make them suitable modular drugs in nanoparticle-assisted drug delivery 
research. In fact, early in 1995 a polyethylene glycol (PEG)-coated (PEGylated) liposomal 
DOX (Doxil) was approved by the FDA for treatment of Kaposi’s sarcoma, and the 
indications were later expanded to include ovarian cancer and multiple myeloma therapy.9 
Doxil demonstrated better efficacy and reduced cardiotoxicity compared to free DOX,10 
and since then many different nanocarriers with encapsulated DOX have been designed and 
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evaluated as therapeutics against breast cancer.11-13 In this thesis, we employed DOX and 
daunorubicin as model drugs to assess polymer-based and protein-lipid based NPs as drug 
delivery systems (DDSs). 
1.2 NANOMEDICINE IN GENERAL 
1.2.1 A brief history 
Nanomedicine has been one of the most rapidly growing research areas in the past two 
decades. The term describes a large group of nanoscale devices, usually with dimensions 
ranging from 1 nm to 1000 nm,3 that are employed in biomedical applications, including 
biosensing,14-16 tissue engineering,17-19 bioimaging,20-22 diagnosis,23-26 and therapy27-29 for a 
range of diseases.  
Table 1. Examples of nanoparticles in clinical studies 
Name Comments Indication Phase Ref 
BIND-014 Docetaxel, Polylactide 
(PLA) and PEG. 
targeting, controlled 
release 
Solid tumors II 30 
CALAA-01 siRNA, cyclodextrin, 
PEG. 
targeting 
Solid tumors I 31 
CPX-1 Irinotecan 
HCI/floxuridine, 
liposome. 
Acute myeloid leukemia II/III 32 
SEL-068 Nicotine, PLAG, lipid, 
PEG. 
Synthetic vaccine particle 
(tSVP) 
Smoking cessation I 33 
 
SP1049C Doxorubicin, Pluronic 
polymeric micelle. 
Advanced 
adenocarcinoma 
II/III 34 
Nanotax Paclitaxel, polymeric 
nanoparticle 
Peritoneal neoplasms I 35 
2B3-101 Doxorubicin, liposome, 
Glutathione  targeting 
Brain metastases of breast 
cancer 
I/II 36 
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The dawn of nanomedicine started in the 1950s and 1960s when two nano-systems, polymer-
drug conjugates (with a single polymer chain) and liposomes, were invented by Jatzkewitz 
and Bangham, respectively.10After that, albumin-based and polymer-based NPs were 
developed in 1970s.37 Another remarkable breakthrough was achieved in the 1980s by Maeda 
et al.38 who discovered the enhanced permeability and retention (EPR) effect,39 which forms 
the cornerstone of passive targeting of solid tumors and has initiated the rapid growth of NP-
assisted cancer therapy systems. Since then, NPs have been extensively investigated for use 
as DDSs, and methods for controlled release,40-44 PEGylated systems,45,46 targeted 
delivery,29,47,48 and gene delivery49-53 have all been developed. To date, dozens of 
nanomedicines have passed clinical trials and been approved by the FDA for clinical use, and 
many more of them are currently in clinical trials (Table 1) or under investigation in the lab. 
These nanomedicines are designed to target various medical problems such as infection,54 
diabetes,55 cancer,56 and other diseases.33,57,58 
 
1.2.2 Classifications of nanomedicine 
The term ‘nanomedicine’ can be defined as the use of nanotechnology to solve biomedical 
problems. 10 There is currently no unified classification of nanomedicines because of the 
broad range of members in this diverse family. However, most nanomedicines can be 
classified as NPs as long as they have a particle-like morphology and nanoscale dimensions. 
Sometimes the term ‘nanovector’ is used for molecule delivery agents or in bioimaging 
applications to describe the hollow or solid NPs that serve to transport other molecules.3 
Based on their chemical composition, NPs can be classified as summarized in Table 2. 
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Table 2. Classification of NPs based on their compositions. 
 
 
 
 
 
 
 
 
 
NPs 
 
 
Inorganic 
NP 
 
Metal NP 
Gold (colloid), silver, metal oxides, etc.  
Superparamagnetic iron oxide nanoparticle 
(SPION)  
supra para magnetic  
 
Non-metal NP 
Silica NP Mesoporous 
Carbon nanotube Cylinder 
 
 
 
 
 
 
Organic 
 
 
 
Bio-derived NP 
Liposome  
Polyamino acid NP  
 
Natural polymer NP 
Polypeptide NP 
DNA NP 
Polysaccharide NP 
 
Engineered 
Polymer NP 
Polymer-drug conjugates  
Micelles (copolymer) Linear, star like, 
hyperbranched  
Dendrimers and Dendrons Unimolecular 
Organic hybrids Conjugated or encapsulated with polymer  
Hybrids  Most inorganic NPs need lipid or polymer 
coating or modifications 
 
 
1.2.3 Structure and advantages of nanomedicine 
Figure 2 shows the typical structure of a NP for drug delivery and diagnostic applications. 
Such NPs usually consist of three parts: a core structure, therapeutic cargo or contrast agent 
(or both for theranostic NPs), and a hydrophilic surface with suitable modifications that 
provide good solubility, enhanced blood circulation time, and improved targeting 
properties.3 Amphiphilic polymer micelles can encapsulate insoluble drugs such as 
paclitaxel in the hydrophobic core and thus enhance the drugs’ solubility.59,60 Due to their 
reduced protein absorption, NPs with PEG protection demonstrate enhanced blood 
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circulation time by evading reticuloendothelial system (RES).61-64 Moreover, the shielding 
of NPs with PEG is helpful in reducing the side effects and enhancing the efficacy of 
chemotherapeutics.23,65,66 For instance, Doxil (a liposome-based nanomedicine with a 
payload of DOX) treated women with metastatic breast cancer has demonstrated similar 
overall survival rate but reduced cardiotoxicity (by evaluating left ventricular ejection 
fraction and congestive heart failure) compared to free DOX 67 Another study also showed 
that patients receiving Doxil had lower level of clinical cardiotoxicity of compared to DOX 
in cumulative doses of 500 mg per m2 (equivalent DOX dose).68 Besides, the core-shell 
structure of a NP can also help protect its payload, and this is particularly useful in NP-
assisted gene therapy, which requires the proper delivery of plasma DNA (pDNA), 
messenger RNA(mRNA), or small interfering RNA(siRNA) to the target while shielding 
the DNA/RNA from degradation by enzymes in the blood stream.69-71 In addition, bio-
functional moieties can be introduced onto the surface of NPs improving the biodistribution 
of NPs at the tumor area due to the active targeting effect.72-74 One example is CALAA-01, 
currently in phase I clinical trials, which utilizes transferrin as the targeting molecules to 
improve the siRNA delivery to solid tumors on which transferrin receptors are 
overexpressed.31 
 
Figure 2. The structure of a typical nanomedicine. 
The fundamental advantage of nanomedicines compared to conventional medicines is that 
they can be designed with multifunctionality in mind.75,76 As mentioned above, the core 
area of the NPs can be used to carry therapeutic payloads. In addition, nanomedicines can 
be designed to carry imaging payloads such as Gd3+,77 SPIONs,78 radionuclides,79 radio 
opaque iodine,80 or Tc-99m,81 and can be traced with modern diagnostic devices like 
magnetic resonance imaging (MRI), positron emission tomography (PET), computed 
tomography (CT), and single photon emission computed tomography (SPECT).82 In 
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particular, polymer-based NPs can be used for diagnostic purposes by simply conjugating 
fluorine-containing copolymers to the system, which makes them detectable by 19F-MRI.83 
This approach is considered promising for solid tumor detection based on three aspects: 
1)19F is the only nature isotope of fluorine and it can only be found in teeth and bones in 
human body, and leading to minimal background influence.84 2) Fluorinated polymer can 
have a high degree of equivalent F to generate strong signal even though F has 17% weaker 
signal than proton.84 3) Fluorinated polymers can be covalently linked to other polymers to 
form copolymer micelles, there is no need to encapsulate or install other contrast agents in 
the NPs to achieve MRI imaging. 
In addition, the large surface area to volume ratio of NPs allows various types of functional 
moieties to be attached and to confer special functions.85 For example, NPs that contain 
cyclic arginine-glycine-aspartic (RGD) peptides can specifically target integrin αvβ3 
overexpression on endothelial tumor cells.86-88 Moreover, functional moieties can allow the 
NP to penetrate through some biological barriers. For example, it has been reported that 
TAT (YGRKKRRQRRR) peptides will help NPs to pass through the blood brain barrier 
(BBB) thus allowing delivery of drugs to the brain to treat infections.89  
 
1.3 NANOMEDICINES VS. TUMORS 
One of the most common areas of nanomedicine application is in the field of oncology, and 
these agents are used for both tumor diagnosis and therapy. The main rationale for using NPs 
in biomedical application is that they can be designed to have several desired functions. 
Several basic requirements have been proposed to define a successful nanomedicine, 
including high efficacy per dose for both imaging and therapeutic applications, targeting to 
the tumor area, and avoiding degradation before arriving at its target.3  
 
1.3.1 Issues regarding anticancer NP development 
Several issues influence the design of a successful NP. The first thing to consider is the 
strategy of the NP’s administration, which normally dictates certain requirements in its 
design. In general, a nanomedicine can be administered into the human body via inhalation, 
oral administration, or injection.90-92 The inhalation strategy is limited to the delivery of 
nanomedicines to the lungs due to problems with aggregation.93 Orally administrated NPs 
have been reported for insulin delivery,94 and this requires NPs to have strong pH stability 
to survive the acidic environment and avoid enzymatic degradation in the gastrointestinal 
tract.95 Currently, the majority of nanomedicines for cancer treatment are administrated by 
intravenous injection.96 This requires the NPs to have a long blood circulation time and low 
to no immunoreactivity. To this end, the size and surface properties for biological 
interactions are also crucial parameters to consider.10  
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Size is important regarding the circulation time of NPs in the blood stream; if they are too 
small or too large this might cause unwanted clearance before the NPs reach their target. 
There are evidences that NPs smaller than 5 nm can be easily filtered out from bloodstream 
via the kidney10,97 and transported to the bladder within 15 min of administration.98 NPs that 
are too large can be removed by sinusoids and clearance via RES.99 Considering the 
requirement for NPs to accumulate at the tumor site via the EPR effect, the ideal size of 
NPs ranges from 10–500 nm.99  
In order to avoid rapid clearance, surface modification of NPs is necessary. The most 
common strategy to evade immunological interactions is to decorate the NP with PEG 
chains.64,100,101 PEG has been shown to be inert to bio-recognition due to reduced protein 
absorption in biophysical environments, and this leads to reduced immunological response, 
reduced RES clearance, and prolonged blood circulation time.100,102,103 However, the presence 
of PEG on surface of liposomes surface have been reported to promote complement (C) 
activation, which results in C activation-related pseudoallergy (CARPA) that is considered as 
the major cause of hypersensitivity reactions.104 All of the three pathways for C activation, 
the classical pathway, alternative pathway and lectin pathway have been found to contribute 
to PEG promoted C activation due to the presence of anti-PEG antibodies, ‘‘protein 
partitioning and exclusion’’ and ficolin/MASP-2-mediation, respectively.105-107 Moreover, the 
concentration of PEG on surface or the linker to NP may influence the C activation.108,109 
This presents a paradox: PEG enhances nanomedicine’s efficacy but can also promote C 
activation in some patients. A possible explanation for this was proposed by Moghimi and 
Szebeni, who pointed out that PEG helps the coated particles to evade macrophages uptake 
regardless of C activation.104,110,111  
 
1.3.2 Targeting solid tumors 
The discovery of EPR effects by Maeda and colleagues in the 1970s is considered to be the 
foundation of nanomedicine research for solid tumor therapy (Figure 3).38,39 This effect 
refers to the phenomenon in which NPs (50–200 nm) can selectively accumulate at a tumor 
site compared to small-molecule drugs. The EPR effect is caused by both the leaky 
vasculature and slow lymphatic drainage of large particles at the tumor site, and it 
constitutes a passive targeting mechanism for solid tumors.112-114 Thus significant efforts 
have been put into designing NPs that can target solid tumors based on the EPR effect. The 
overall strategy is to enhance the blood circulation time of NPs to allow them to reach the 
tumor area and to accumulate there. In particular, NPs coated with inert molecules such as 
PEG reduce protein opsonization and phagocytic elimination.96 
Besides passive targeting, active targeting strategies have also been investigated. A 
common strategy is to attach molecules to the surface of the NP that have higher affinity for 
receptors on tumor cells so as to enhance receptor-mediated uptake. Small molecules like 
folic acid115 and transferrin,116 aptamers,48 peptides,89 and antibodies117 have been widely 
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explored for active targeting of NPs. One successful example currently in clinical trials is 
BIND-014, which is a polymer-based NP for targeted delivery of docetaxel to prostate-
specific membrane antigen-bearing solid tumors.30 Another one in clinical trial is a lipid 
base nanomedicine, SGT-53, which carries a pDNA encoding wild type p53 tumor 
suppressor and has a single-chain antibody fragment (scFV) that targets transferrin receptor 
(TfR) on tumor cells.118-120 Other nanomedicines with Tf conjugation, such as MBP-426 
and CALAA-01, are also under clinical trials for cancer treatment via targeting TfR on 
tumor cells. 31,118,121 
 
 
Figure 3. Illustration of the EPR effect. NPs can penetrate to tumor tissue through the 
leaky vasculature and be trapped there due to the slow lymphatic drainage of large particles 
at the tumor site. 
 
The benefits of active targeting are still debated. Dawson et al. reported that transferrin-
labeled NPs can lose their targeting capability in protein-rich environments, due to the 
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formation of a protein corona.122 Park et al. demonstrated through in vivo experiments that 
antibody directed NPs did not increase tumor localization via active targeting but enhanced 
cancer cell uptake.123 Similar effects was also observed by Davis et al. showing that Tf-
targeted NPs had similar biodistribution and tumor localization but more effective siRNA 
delivery compared to non-targeted NPs, suggesting the Tf ligand enhanced internalization 
rather than localization of NPs in tumor cells.124 Moreover, even if a targeting moiety is 
successfully linked to an NP and remains functional, there is still no guarantee that the 
receptor is only over-expressed on the target cell population.96 This is another drawback to 
the use of folic acid or transferrin-labeled NPs to specifically target tumor cells because 
receptors for these molecules are expressed on several types of cells.125,126 Based on these 
concerns, the efforts of this thesis were only focused on exploring NPs that can achieve 
passive targeting. 
 
1.3.3 Diagnostic function 
The use of conventional diagnostic agents such as chelated Gd3+ for MRI and 
radionucleotides for SPECT and PET are hindered by their short lifetime in the blood 
circulation and their poor biodistribution at the tumor site.113 The development of 
nanomaterials has provided a new way to formulate contrast agents for the diagnosis of 
tumors. Some types of NPs can act as contrast agents by themselves due to their intrinsic 
properties. For instance, metal-based NPs like SPIONs can serve as imaging agents for MRI 
due the their intrinsic magnetic resonance property.127 Gold NPs can generate good contrast 
in human tissues making them promising for CT applications.128  
In most cases, however, NPs with diagnostic function are formulated by integrating contrast 
agents within the nanomaterials. Incorporated with suitable imaging modalities, NPs can 
serve as contrast agents in modern medical imaging techniques including CT, MRI, PET, 
SPECT, and ultrasound.129 Inorganic NPs like mesoporous silica NPs can be designed to 
carry different types of imaging modalities for different diagnostic strategies.130 To date, 
organic NPs including both bio-derived (peptides and lipids) and engineered polymers have 
been widely used as carriers of both imaging agents and therapeutic molecules due to their 
good biocompatibility. Polymer modification is very common in the development of 
inorganic NPs for imaging applications. Such modification imparts the system with better 
solubility, better biocompatibility, and longer blood circulation time. The most common 
strategy is adding a hydrophilic polymer such as PEG to the inorganic NPs. Recently, pure 
polymer NPs by themselves have been shown to be useful as contrast agents for MRI 
imaging. Morel et al. applied perfluoropolyether to label dendritic cells and achieved in 
vivo tracking of those cells in mice using 19F-MRI.131 Later Wooley et al developed 
trifluoroethyl methacrylate (TFEMA) contained amphiphilic polymer micelles that can 
generate detectable 19F-MRI signal and deliver DOX for cancer treatment.132,133 
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1.3.4 Anticancer drug delivery 
Besides diagnostic applications, NP formulation strategies have also focused on therapeutic 
delivery. The original application of nanomedicines was to deliver anticancer drugs or 
proteins to achieve better therapeutic effects.2,134 With the development of gene therapy 
over the past decade, genetic agents have become commonly formulated drugs that can be 
delivered by nanovectors.31 
The motivation to develop nanovector-assisted delivery systems is to overcome the 
common disadvantages of conventional chemotherapy and gene therapy. Low molecular 
weight anticancer drugs have a random distribution throughout the body and usually come 
with negative side effects.2 Additionally, some drugs like paclitaxel have very poor 
solubility in aqueous solution. Gene therapy agents, such as pDNA and siRNA, are not 
stable in the blood stream due to degradation by nucleases and thus have short biological 
halflives.135 Encapsulation of drugs by polymer platforms can greatly improve the drug 
solubility and alter the biodistribution of these anticancer agents by extending their blood 
circulation time and assisting in their accumulation at the tumor through both active and 
passive targeting, such as the EPR effect.39,112 Furthermore, the unwanted side effects 
caused by chemotherapeutics can be minimized due to their better biodistribution and 
controlled release from non-toxic polymers. Gene therapy cargos can also be protected 
from enzymatic degradation and random protein absorption.67,68 In addition, active 
targeting moieties can also be built into the nanovectors in order to achieve even better 
therapy efficacy by improved targeting to solid tumors.87,96,136 
On a more complex level, nanomedicines are able to cross bio-barriers that are difficult for 
conventional chemotherapy and gene therapy agents. At the tissue and organ level, the BBB 
is considered the main obstacle that blocks effective therapy for brain tumors. NPs with 
proper surface coating can assist drugs in crossing the BBB. For instance, NPs coated with 
polysorbate 80 or glutathione have been shown to improve chemotherapeutic delivery for 
brain cancer treatment.137,138 Bio-barriers also exist on the cellular level. For example, 
clathrin-mediated endocytosis usually results in endosomal and lysosomal entrapment 
where the acidic environment (pH 4.0–6.5) leads to degradation of genetic agents and the 
detoxification of chemotherapeutics.139-141 One solution to this problem is to alter the 
uptake pathway of the nanomedicine by introducing receptors for the cavoline-mediated 
pathway.140,142 Considering the difficulty in maintaining the bioactive function of ligands 
on the nanomedicine surfaces due to the effect of protein coronas, an alternative is to design 
endosomal and lysosomal escapable systems that can relocate the therapeutic payloads back 
to the cytosol and allow nuclear localization. 143-145 
Another advantage of nanomedicine-assisted drug delivery is that the drug release profile can 
be tailored by tuning the composition of the NPs or by adding a stimulus-responsive property 
to the system. Diffusion-controlled delivery means controlling the drug release through the 
chemical or architectural design of the nanovectors. For example, it is commonly believed 
that a NP with strong hydrophobic core interactions with the drug cargo tends to have slower 
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release of hydrophobic cargos. The release kinetics can therefore be tailored by carefully 
altering the hydrophobic to hydrophilic ratio of the polymer system. For triggered drug 
release, the most common strategy is to design a pH-responsive system. The idea of this 
strategy is based on the fact that pH values between healthy tissue (pH 7.4) and tumor tissue 
(pH 6.5-7.2) are different.146 Nanocarriers can be designed to have low or no drug release at 
pH 7.4 but rapid drug release at lower pHs. Besides the pH responsiveness, other exogenous 
stimuli-responsive nanomedicines have been designed that show sensitivity to changes in 
temperature, magnetic field, light, and ultrasound.147-150 
In addition, NPs can also help to overcome multidrug resistance. This can be achieved via the 
intrinsic physical chemical properties of the NP151 or by co-delivery of chemotherapeutics 
and siRNA that inhibit the overexpression of p-glycoprotein on cancer cells.152 
 
1.3.5 Theranostic systems 
Recently, nanomedicines with both diagnostic function and drug delivery capability have 
become the focus of intense research activity. Such nanoscale systems are called theranostic 
NPs where the term ‘theranostic’ is derived from the combination of the words ‘therapy’ and 
‘diagnostic’.153 The primary goal of theranostic devices is to enable detection and treatment 
of diseases in a single procedure.113 Such systems provide a powerful and non-invasive 
approach to tracing drug delivery, monitoring drug release, and assessing drug efficacy.154 
Most types of NPs used in imaging or drug delivery applications can be redesigned as 
theranostic platforms. Thermally cross-linked superparamagnetic iron oxide nanoparticles 
(TCL-SPIONs) with carboxyl groups in the polymer coating layers can incorporate DOX 
via electrostatic interactions. The resulting DOX–TCL-SPION enables the delivery of DOX 
to tumors along with the detection of tumors by MRI.155 Besides imaging payloads and 
drugs, targeting moieties can also be integrated to facilitate targeted delivery. For instance, 
magnetic IONPs conjugated with the amino-terminal fragment peptide can perform targeted 
delivery of gemcitabine to pancreatic cancer in mice and can generate detectable MRI 
signals during the process.156 Furthermore, multimodal imaging and therapy can also be 
achieved. A PEGylated nanocomplex with biotinylated antibodies has been shown to be 
capable of mediating MRI and near-infrared fluorescence imaging while providing 
photothermal therapy functionality.113  
Recently, fluorinated polymer NPs have been considered as a promising approach to 
developing theranostic NPs due to their ability to generate 19F-MRI signal which has few 
interference signals in vivo and to allow the possibility to tailor the drug-release profile.83 
The third paper in this thesis focused on the development of such polymer systems and 
evaluated them as theranostic systems in vitro. 
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1.4 POLYMER-BASED ANTITUMOR NANOMEDICINE 
Polymer-based nanomedicine refers to non-viral nanovectors that contain polymers such as 
polymer-inorganic hybrids, polymer-drug conjugates, polymer-protein conjugates, 
polyplexes, and polymer micelles.157 Common properties of successful polymer-based 
nanomedicines for anticancer applications are that they 1) are all water-soluble; 2) can 
improve the solubility of insoluble anticancer agents; 3) are non-toxic or only slightly toxic to 
healthy tissue; 4) can evade the immune system; 5) have long blood circulation times; and 6) 
can enhance the bioavailability of therapeutics or imaging payloads at tumor sites.157 Based 
on the research in this thesis, two types of polymer nanomedicines are introduced below. 
 
1.4.1 Dendritic polymer systems 
Most polymer-based nanomedicines currently approved for clinical use have linear polymer 
architectures. However, significant efforts have been put into the development of polymer 
nanomedicines with more complex architectures such as dendritic polymer systems. Two 
kinds of dendritic polymers – dendrimers (including dendrons) and hyperbranched polymers 
– are commonly used in anticancer research (Figure 4 A). Dendrimers and dendrons are 
perfectly branched dendritic polymers with well-controlled size, shape, and molecular weight 
and show monodispersity.158,159 They are usually synthesized from either the divergent 
approach (from the inside out) or convergent approach (from the outside in) via multi-step 
reactions.160 The resulting macromolecules have a central core bound to repeating units that 
form layer-like structures. Each layer of the repeating units is called one ‘generation’. Based 
on the number of generations and the chemical composition of the repeating units, the 
number of terminal groups on the outside layers can be determined. 
Compared to dendrimers and dendrons, hyperbranched polymers can be more quickly and 
easily produced via one-step polymerization from ABn monomers (n ≥ 2).161 However, the 
resulting hyperbranched polymers are structurally imperfect because of the occurrence of 
linear chains due to random competitive reactions during the synthesis.160 Therefore, 
hyperbranched polymers do not have a real ‘generation’ number like dendrimers and 
dendrons, and the term ‘pseudo generation’ is usually applied to describe the statistical 
‘generation’ of hyperbranched polymers.162 
Both dendrimers (dendrons) and hyperbranched polymers have been investigated as 
candidates for anticancer treatment. For example, polyamidoamine (PAMMA) dendrimers 
have been used in DNA or siRNA delivery due to their cationic property.69,163 More 
recently, poly-2,2-bis(methylol) propionic acid (bis-MPA)–based hyperbranched polymers 
demonstrated good potential in drug and gene delivery because of their non-toxic and 
biodegradable properties.164,165 In addition, one of their derivative structures – dendritic 
linear (DL) (or linear dendritic) hybrids (Figure 4B) that usually consist of a dendron head 
and a linear polymer tail – has also been investigated and shown to have promising features 
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as a drug or gene delivery system.166-168 
 
 
Figure 4. Dendritic polymers in biomedical applications. Structures of A) dendrimers, 
dendrons, and hyperbranched polymers and B) dendritic-linear polymers. 
 
1.4.2 Unimolecular polymer NPs 
The increased interest in developing polymer-based unimolecular micelles as nanovectors 
comes from the instability of copolymer micelles in vivo. Amphiphilic copolymers can self-
assemble into micelles, which have a typical core-shell structure consisting of a hydrophobic 
core and a hydrophilic surface (shell). Polymer micelles have been investigated as desirable 
carriers for imaging and therapeutic payloads because they have high loading capacity, 
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increased solubility of hydrophobic drugs, and the ability to evade RES clearance and to 
increase the EPR effect.169 However, the use of classical multi-molecular micelles is hindered 
by their intrinsic limitation regarding the structural stability of the micelles. Block copolymer 
micelles can only maintain their structure above the critical micelle concentration (CMC), 
otherwise they will disassemble.170 Most NPs for antitumor applications are administered 
through intravenous injection leading to unavoidable dilution in the bloodstream that can 
cause disassembly and burst release of the cargo.79,171 In order to overcome the CMC issue, 
Wooley et al. introduced the ‘shell cross-linked’ concept to enhance the stability of polymer 
micelles in vivo.77,172,173 An alternative approach is to develop core-shell type unimolecular 
micelles formed from a single polymer macromolecule. One strategy is to construct 
dendrimers or dendrons with controlled molecular weight, size, and shape; however, the 
multi-step synthesis of such molecules is tedious and time consuming.158 Hyperbranched 
block copolymers can be designed as unimolecular macromolecules by covalently binding 
hydrophilic polymers such as PEG to the hydrophobic dendritic core via chain extension. The 
covalent linkage between the core and shell imparts the micelles with excellent stability, and 
the synthesis procedure is less time consuming compared to dendrimers.171,174 In paper IV, 
we developed a library of such polymers and explored them as DDSs. 
 
1.5 LIPOPROTEIN-BASED NANOPARTICLS 
Although ‘nanoparticles’ is a relative new word, naturally occurring NPs have always been 
present inside us. The idea of using liposomes as artificial delivery vectors is actually inspired 
by the structure of the cell membrane, which mainly consists of a double layer of 
phospholipids and various kinds of proteins. There is one type of endogenous NP in our 
body, called lipoprotein, that is very similar to the cell membrane and consists mainly of 
proteins and phospholipids.140 Lipoproteins transport hydrophobic cholesterol among cells 
from different organs via the circulatory system.175 As a natural substance in the body, there 
is no biocompatibility issue for lipoproteins. Furthermore, they have a hydrophobic core 
that can encapsulate hydrophobic molecules through reconstitution, and the hydrophilic 
surface allows further modifications to generate multifunctional NPs.175-178 Therefore, 
efforts have been made to produce artificial lipoprotein mimics for diagnostic and 
therapeutic applications.179-181 Recently, statins were reconstituted in high-density 
lipoprotein NPs dually labeled with gadolinium and the fluorescent dye Cy5.5 that allow 
both MRI and near infrared fluorescence imaging tracking. Both in vitro and in vivo 
analysis showed that the NP could inhibit inflammation in atherosclerotic plaques.182 A 
lapatinib-incorporated lipoprotein NP has also been studied as a breast cancer treatment.183 
In paper VI, we proposed a new type of lipoprotein-like NP, called salipro-NP, that consist 
of saposin A and hydrophobic phospholipid-containing substances. Such NPs were 
evaluated as a DDS and a potential vaccine carrier. 
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1.6 NPS IN DIFFERENT PAPERS 
In this thesis, several polymer based NPs and one lipoprotein like NP system were 
investigated. The differences among these systems and the significant of study in each 
paper are summarized in Table 3. 
Table 3. NPs involved in this thesis. 
Paper NO. Description of NPs Significance 
I Hyperbranched dendritic linear polymer micelles vs. 
dendrons dendritic linear polymer micelles 
Hyperbranched polymer can be 
produce in large scale 
II Hyperbranched copolymer micelle with Boltorn 
(polyester) core and PEG tails 
Uptake mechanism of 
hyperbranched polymer NPs 
III Fluorinated copolymer micelles with different 
structures of the hydrophobic core 
Theranostic systems, allow 19F-
MRI imaging and drug delivery 
IV Unimolecular micelles with hyperbranched cores Eliminate CMC issue 
V Histamine functionalized block copolymer micelles Endo-lysosomal escape property 
VI Lipoprotein NP, consisted of saposin A and 
phospholipids 
Multifunctional, including drug 
delivery and antigen carrier (NP 
based vaccine) 
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2 AIM OF THE THESIS 
The overall aim was to develop NP carriers as drug delivery platforms for breast cancer 
treatment. The specific aims of the studies within this thesis were to: 
1. Establish a method to develop hyperbranched linear polymers and to determine their 
capability as a DDS compared to dendrimers.  
2. Investigate the cellular uptake mechanism and intracellular trafficking pathway of bis-
MPA–based hyperbranched polymers. 
3. Develop a multifunctional theranostic NP system that can deliver DOX and allow for 
imaging via 19F-MRI signals. 
4. Develop unimolecular polymer NPs to avoid CMC problems and to evaluate them as 
a DDS. 
5. Evaluate the effects of histamine modification on polymer NPs to design NPs with 
endolysosomal escape capabilities. 
6. Design and develop a bio-derived multi-functional NP system that can delivery 
various molecules. 
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3 MATERIALS AND METHODS 
3.1 MATERIAL SYNTHESIS 
The detailed synthetic procedures can be found in papers I–V. The expression and 
purification of saposin A, bacterial peptide transporters POT1 and POT2, and human 
membrane protein Synaptophysin as well as the generation of salipro particles are described 
in detail in paper VI. 
 
3.2 CHARACTERIZATION OF POLYMERS 
3.2.1 Size exclusion chromatography (SEC) 
In papers I, III, and IV, SEC (Dimethylformamide, DMF) was performed with a TOSOH 
EcoSEC HLC-8320GPC system equipped with an EcoSEC RI detector and three columns 
(PSS PFG 5 µm, Microguard 100 Å, and Microguard 300 Å) from PSS GmbH. The mobile 
phase was 0.2 mL·min−1 DMF with 0.01M LiBr, and the system was run at 50 °C and 
calibrated with narrow linear poly(methyl methacrylate) standards using a conventional 
calibration method. Corrections for flow-rate fluctuations were made using toluene as an 
internal standard. PSS WinGPC Unity software version 7.2 was used to process the data. 
In paper I, SEC (CHCl3) was performed with a Verotech PL-GPC 50 Plus system equipped 
with a PL-RI detector, and two PLgel 10 µL mixed (300 × 7.5 mm) columns from Varian 
were used. The mobile phase was 1 mL·min−1 CHCl3, and the system was calibrated with 
polystyrene standards. 
For the detailed method of size exclusion chromatography–multiple angle laser light 
scattering (SEC-MALLS), please see paper IV. 
 
3.2.2 Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
A Bruker UltraFlex MALDI-TOF MS with a SCOUT-MTP Ion Source (Bruker Daltonics, 
Bremen) was used with a N2 laser (337 nm) and reflector design. SpheriCal® calibrants 
were used to calibrate the instrument, and the resulting spectra were analyzed with the 
FlexAnalysis software version 2.2 from Bruker Daltonics. 
 
3.2.3 Critical micelle concentration (CMC) 
The CMC of micelles in PBS solution was determined by fluorescence spectroscopy (Varian 
Cary Eclipse) by collecting emission spectra using an excitation wavelength of 332 nm at 
room temperature. 
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3.2.4 Nuclear magnetic resonance (NMR) 
A Bruker Avance 400 MHz NMR instrument was used to record 1H-NMR and 13C-NMR 
(1D) spectra for structure analysis. CDCl3, (CD3)2SO, D2O or MeOD were used as the 
solvent, and the residual solvent peak was used as the internal standard. 
The detailed methods of 1H NMR and 19F-NMR diffusion can be found in papers I and III. 
 
3.3 PREPARATION OF NPS AND DRUG-LOADED NPS 
Polymer-based NPs were prepared via a two-phase emulsion method. A certain amount of 
polymer was dissolved in PBS and mixed with 1 mL organic solvent (CHCl3 or CH2Cl2). 
Polymers self-assembled into NPs after the evaporation of the organic solvent while stirring 
overnight. DOX-encapsulated NPs (DOX-NPs) were prepared in a similar way by mixing 
DOX dissolved in organic solvent with the polymer dissolved in PBS solution. DOX-NPs 
formed after the evaporation of organic solvent while stirring overnight. Free DOX was 
removed by spin filtration with a molecular weight cut-off (MWCO) of 3 kDa. The 
concentration of DOX in the NPs was measured by comparing UV absorbance at 490 nm of 
samples diluted with DMF:H2O (4:1) to a standard curve (five replicates). 
In paper VI, daunorubicin was incorporated into salipro-NPs by first mixing daunorubicin 
stock solution with brain-lipid solution and then adding saposin A to the system. The 
mixture was incubated for 10 min at 37 °C then purified with a HiLoad SuperdexTM 200 
16/60 GL column using an ÄKTA Explorer TM 10 chromatography system (both from GE 
Healthcare). UV absorbance was measured at 280 nm (protein) and at 480 nm 
(daunorubicin). The concentration of incorporated daunorubicin was determined by 
comparing UV absorbance at 488 nm using a UV spectrometer (NanoDrop ND1000, 
Thermo Fischer) to daunorubicin standard curves. Detailed information on this procedure 
and the methods of incorporation of other molecules are described in paper VI.  
 
3.4 CHARACTERIZATION OF NPS 
3.4.1 Transmission electron microscopy (TEM) 
The morphology and dry size of NPs (papers III, IV, and V) were observed via TEM. For 
the polymer NPs, 3 µL each of NP or DOX-NP (ca. 50 µg·mL−1 in PBS) was added and kept 
for 20 seconds on a glow-discharged, carbon-coated Formvar grid (Electron Microscopy 
Sciences). The liquid sample was removed and the grid was stained with 2% (w/v) aqueous 
uranyl formate solution for another 20 seconds. TEM images were obtained with an FEI 
Morgagni 268(D) Transmission Electron Microscope at 80 kV at 44,000× magnification. 
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3.4.2 Dynamic light scattering (DLS) and zeta potential 
The hydrodynamic size and surface charge of NPs were measured with DLS and zeta 
potential, respectively, with a Malvern Zetasizer NanoTZ. Samples were measured at 25 °C 
or 37 °C in filtered PBS. Polymer NPs were analyzed at a concentration of 0.25 mg·mL−1, 
and salipro particles were measured at 1.0 mg·mL−1. DOX-NPs were evaluated directly 
after the removal of free DOX. Each sample was measured by running 10 scans, and at 
least three parallel measurements were performed. 
 
3.4.3 In vitro 19F-MRI 
The 19F-MRI analysis of NPs was conducted with an MR-400 scanner (Varian Inc, Yarnton, 
UK). NPs (10 mg·mL−1 in PBS) were loaded into plastic syringes (d = 6 mm) and placed in a 
fixed-tune surface coil with a curved housing designed for mouse head 19F-MRI (Rapid 
Biomed, Rimpar, Germany). Images were acquired by employing a gradient echo sequence 
with tr and te of 200 ms and 1.66 ms, respectively, and a flip angle of 20°. The matrix size 
was set as 64 × 64 mm2 equivalent to 48 × 48 mm2 for a slice thickness of 4 mm. 
 
3.5 IN VITRO DRUG RELEASE 
The drug release property of different NP systems was evaluated in a buffer system in vitro. 
In papers I, III, IV, and V, 3 mL of free DOX or DOX-NPs were loaded into dialysis 
cassettes (MWCO 3,500, Slide-A-Lyzer G2, Thermo) and suspended in 4 L of PBS (pH 7.4, 
pH 6.0 for paper V) solution with magnetic stirring at 37 °C. Aliquots of 10 µL sample 
(triplicates) from the inside of the cassettes were collected at 0, 2, 8, 10, 12, 24, 48, and 72 
h and transferred into 96-well fluorescence plates. A total volume of 100 mL DMF in H2O 
(4:1) was added to each sample to disaggregate the NPs, and the fluorescence intensity was 
determined with a multi-mode microplate reader (BioTek Synergy™ MX) at the 
wavelength of 485/595 (excitation/emission) nm. 
In paper VI, 35 µL of free daunorubicin or daunorubicin-incorporated NP solutions were 
loaded into dialysis units (Slide-A-Lyzer, Thermo) and suspended in 1 L PBS (pH 7.4) at 
37 °C with magnetic stirring. Aliquots of 10 µL (triplicates) were collected from the inside 
of the units at 0, 4, 12, 24, 48, and 72 h. A total volume of 100 mL of DMF in H2O (4:1) 
was added to each sample to disaggregate the NPs, and the fluorescence intensity was 
determined with a multi-mode micro plate reader (BioTek Synergy™ MX) at the 
wavelength of 485/595 (excitation/emission) nm. 
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3.6 CELL-BASED EXPERIMENTS 
3.6.1 Cell lines 
Human breast cancer cell lines MDA-MB-231, MDAMB-468, and MCF-7 were purchased 
from American Type Culture Collection (ATCC), and the mouse monocyte macrophage 
cell line RAW 264.7 was obtained from Prof. Agneta Richter-Dahlfors, Karolinska 
Institutet. Cells were maintained with complete Dulbecco's modified Eagle medium 
(DMEM) (pH 7.4) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U·mL−1 
penicillin-streptomycin, and 2 mM glutamine solution at 37 °C with 5% CO2. Breast cancer 
cells were harvested by trypsin, and RAW 264.7 cells were harvested by scraping. 
 
3.6.2 3D cell models 
3D spheroid models were established with MDA-MB-231 cells by adapting the methods 
described by Heuchel et al.184 Briefly, cells were harvested, washed, and seeded onto 96-well 
plates (round bottom) at a concentration of 3000 cells/100 mL DMEM medium (phenol red-
free, supplemented with 20% methylcellulose). Cells were cultured at 37 °C for 48 h for the 
formation of 3D spheroids. 
 
3.6.3 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assays 
Cellular mitochondria function was measured by MTT assays. Cells were harvested and 
seeded into 96-well plates at a concentration of 5 × 104 cells/well (in 100 µL DMEM) and 
cultured for 24 h. The medium was replaced with 100 µL of fresh medium containing 
various concentrations of NPs, DOX-NPs, or DOX (4 or 5 parallel wells for each 
concentration). A total volume of 10 µL of MTT solution (5 mg·mL−1) was added to each 
well after 12, 24, 48, or 72 h and then 100 µL sodium dodecyl sulfate (SDS) solution (10%) 
was added to stop the assay. The absorbance was measured after an additional 18 h in a 
plate reader at 570 nm. (BioTek Synergy™ MX) (Papers I–V) 
 
3.6.4 ATP luminance viability assay 
In paper V, the viability of MDA-MB-231 cells in 2D and 3D culture were also evaluated 
via CellTiter-Glo Luminescent Cell Viability Assay (Promega). Briefly, 3D spheroids or 
2D cultures in 96-well plates were incubated for 72 h in 200 mL of DMEM medium 
(phenol red free) containing NPs (0.1–100 µg·mL−1), DOX, or DOX-NPs (0.01–10 
mg·mL−1). Six replicates were set for each sample concentration. A total of 120 mL of 
medium was removed carefully (to avoid loss of spheroids), and 80 mL of CellTiter-Glo 
Luminescent reagent was added to each well. Plates were shaken gently in the dark for 20 
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min. The mixtures from each well were then transferred into white 96-well plates, and the 
resulting luminescence was quantified with an Infinite F200 plate reader.  
 
3.6.5 Apoptosis assays 
Cells were seeded on 6-well plates at a concentration of 5 × 105 cells per well and pre-
cultured for 24 h before treatment. Cells were treated with designated amounts of DOX, DOX-
NPs, or NPs for 12, 24, 48, or 72 h (see papers III and V). Cells were then harvested and washed 
with PBS twice and stained with fluorescein isothiocyanate (FITC)-labeled Annexin V and 
propidium iodide (PI). Samples were analyzed with either a FACSCalibur (BD Science) 
(paper III) or an Accuri C6 (BD Science) (paper IV) flow cytometer by collecting 10,000 
events. FITC fluorescence was excited by the 488 nm laser and collected on the FL-1 
(533/30 nm) detector, and PI signal was collected on the FL-3 (>670 nm) detector. Data 
were analyzed using the CellQuest and BD Accuri C6 Analysis software, respectively. 
 
3.6.6 Quantitative cellular uptake analysis 
In paper II, the cellular fluorescence was quantified as the fluorescent intensity normalized 
to milligrams of cell protein. Cells were seeded on 12-well plates at a concentration of 2 × 
105 cells per well and pre-cultured for 24 h. Cells were then treated as follows. For the 
concentration-dependent assay, cells were treated with 0–300 µg·mL−1 of NPs for 3 h. For the 
time-dependent assay, cells were treated with 300 µg·mL−1 of NPs for 1, 2, 4, 6, 12, or 24 h. 
For the temperature-dependent assay, cells were treated with 300 µg·mL−1 of NPs for 3 h at 
37 °C or 4 °C. For the serum-dependent assay, cells were treated with 300 µg·mL−1 of NPs 
for 3 h with or without serum. For the endocytotic inhibition assays, cells were incubated 
with inhibitors first (for details see paper II), then washed and treated with 300 µg·mL−1 of 
NPs for 3 h. After treatments, cells were lysed in 100 µL of cell lysis buffer for 15 min. Then 
10 µL of cell lysate was used to quantify the protein amount using a BCA assay, and the 
fluorescence of the remaining lysate was measured by a multi-mode microplate reader 
(BioTek Synergy™ MX) at a wavelength of 490/520 (excitation/emission) nm. 
In paper III, cellular uptakes of NPs and DOX-NPs were compared using a flow cytometer. 
Cells (5 × 105) were seeded, treated with 5 µg·mL−1 DOX or DOX-NPs and 100 µg·mL−1 
FITC labeled NPs (FITC-NPs), washed, and harvested as in the apoptosis assay. Cells were 
re-suspended in 0.5 mL of PBS for immediate analysis by a FACSCalibur (BD Science) flow 
cytometer collecting 10,000 events. The fluorescence of the FITC-NPs was excited by the 
488-nm laser and collected in the FL-1 channel (530/30 filter/bandpass), and DOX 
fluorescence was excited by the 635-nm laser and collected in the FL-4 channel (661/16 
filter/bandpass). Data were analyzed using the CellQuest software. 
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3.6.7 Intracellular tracking of NPs (confocal microscopy) 
For 2D cell cultures, cells (5 × 105 cells/well in papers II, III, IV, and VI and 1 × 105 
cells/well in paper V) were seeded on 6-well or 12-well plates with coverslips at the bottom 
(papers II, III, and VI) or on glass-bottom dishes (P35G-0-10-C, MatTek, in paper V) and 
pre-cultured for 24 h. Cells were then treated with samples at the designated concentrations 
for different periods of time (details are in the respective papers). Cells were washed and 
stained with fluorescent dyes before or after being fixed with 4% formaldehyde (details in 
the papers). For live-cell imaging, no fixation was required. Cells on the slides were washed 
and sealed with mounting medium. Fluorescence was observed with either a FV1000 
Olympus confocal microscope (papers II, III, and VI) or a Zeiss LSM 510 Meta confocal 
microscope with a temperature control chamber (paper V). For detailed laser settings, 
please see papers II–VI. Images were acquired with FV1000 software (FV10-ASW) or 
LSM software, and co-localization was analyzed with the ImageJ software. 
For 3D cell cultures, spheroids were obtained as described in the cell models section. The 
spheroids were then incubated for 4 h in 2 mg·mL−1 of DOX or DOX-NPs. The spheroids 
were transferred into Eppendorf tubes and gently spun for 15 s. The supernatant was 
removed, and fresh PBS was added. The washing step was repeated three times. Cells were 
stained with Hoechst (5 mg·mL−1), and LysoTracker Deep Red (100 nM) or MitoTracker 
Deep Red FM (100 nM) was then added and incubated for another 15 min. Spheroids were 
washed another three times then carefully suspended on glass-bottom dishes (P35G-0-10-C, 
MatTek). A Zeiss LSM 510 Meta confocal microscope with a temperature control chamber 
was used to observe the samples. Detailed settings can be found in paper V. Data were 
collected with the LSM software, 3D images were reconstructed with the Imars software, 
and co-localization was analyzed with ImageJ. 
 
3.7 STATISTICAL ANALYSIS 
All the quantitative data from DLS, viability assays, drug release assays, and 
apoptosis/necrosis analysis are presented as mean values with standard deviations (SD). 
Statistical analysis was performed via ANOVA followed by a post hoc test (Tukey HSD, 
alpha 0.05) using KaleidaGraph v4.1 (Synergy Software, Reading, PA).  
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4 RESULTS  
4.1 PAPER I. SIDE BY SIDE COMPARISON OF DENDRITIC LINEAR HYBRIDS 
AND THEIR HYPERBRANCHED ANALOGS AS MICELLAR CARRIERS OF 
CHEMOTHERAPEUTICS 
Hydrophilic DL hybrids can form micelles in aqueous environments and have been shown 
to be promising in drug delivery applications.185 However, the synthesis of the dendron 
components involves multiple steps, and the procedure is very time consuming.158 Thus the 
use of DL hybrids as a DDS has been hindered by the difficulty in producing large amounts 
of material. 
To solve this problem, we focused our efforts on developing a novel method for the rapid 
and large-scale synthesis of DL hybrids. The resulting DL hybrids are hyperbranched DL 
hybrids (HBDL), which were synthesized via Fisher esterification reactions of bis-MPA 
starting from a monomethylether linear PEG (mPEG, MW 5000 g·mol−1) in one step. These 
HBDL were further compared to their perfect DL analogs produced through copper(I)-
catalyzed azide–alkyne cycloaddition (CuAAC)-based click chemistry. 
HBDL hybrids of the second (DL PEG-[HBG2]-(OH)4 ) and third pseudo-generation (DL 
PEG-[HBG3]-(OH)8) were first synthesized using mPEG and bis-MPA monomers via 
Fisher esterification reaction on a 50 g scale. They were then end-capped with the addition 
of a layer of bis-MPA monomers to their hydroxyl groups. Benzylidene decoration was 
then introduced to the final layer of bis-MPA to increase the hydrophobicity of the system 
for further drug encapsulation. The resulting HBDL hybrids – DL PEG-[HBG3]-(Bz)4 and 
DL PEG-[HBG4]-(Bz)8 – were further examined by 1H-NMR and SEC to confirm their 
structural integrity, and their degree of branching was calculated from 13C-NMR 
measurements.186 The perfectly branched DL with benzylidene decoration in generation 
three (DL PEG-[G3]-(Bz)4) and four (DL PEG-[G4]-(Bz)8) were synthesized via CuAAC 
click chemistry187 by clicking mono PEG5k-acetylene to Azide-[G3]-(Bz)4 or Azide-[G4]-
(Bz)8. The structural integrity and perfection were confirmed by 1H-NMR and MALDI-ToF 
MS, respectively. 
In the next step, we obtained micellar NPs and DOX-NPs via the two-phase emulsion 
method, and the size of NPs/DOX-NPs was determined by DLS. DL micelles tended to 
have smaller size compared to HBDL micelles with the same (pseudo) generation 
according to number-averaged DLS. After DOX loading, the size of the micelles increased 
significantly and aggregation was found for DOX-HBDL NPs indicating insufficient stealth 
or steric repulsion from PEG segments. Further study on drug release in a PBS system 
showed a burst release (80% of the DOX was released within 12 h) of all four materials 
suggesting that the hydrophobic compartment was not large enough to effectively transport 
the drug. 
To further evaluate the biocompatibility of HBDL and DL micelles and the efficacy of 
DOX-loaded NPs, we performed MTT assays to measure the mitochondrial function of the 
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MDA-MB-231 breast cancer cell line. Mitochondrial activity was higher than 90%, so both 
the DL and HBDL micelles were considered to be non-toxic to MDA-MB-231 cells in the 
range of 0.1–100 µg·mL−1 after 48 h incubation. However, DOX-NPs displayed a dose-
dependent toxicity against the cells over the same incubation time. Significantly lower 
mitochondrial viability was found for DL PEG-[HBG3]-(Bz)4-DOX, DL PEG-[HBG4]-
(Bz)8-DOX, and DL PEG-[G4]-(Bz)8-DOX compared to free DOX and DL PEG-[G3]-
(Bz)4-DOX at a DOX concentration of 10 µg·mL−1 (approximately equivalent to 100 
µg·mL−1 of NPs). This indicates that HBDLs are able to enhance the efficacy of the drug. 
In summary, the bis-MPA-based HBDL hybrids can be produced on a large scale and much 
more quickly through Fisher esterification reactions. The HBDL NPs are non-toxic and can 
enhance drug efficacy in breast cancer treatment. With suitable modification of PEG 
molecules and hydrophobic compartments, HBDL NPs are promising for drug delivery 
applications.  
 
4.2 PAPER II. ENDOCYTIC UPTAKE AND INTRACELLULAR TRAFFICKING 
OF BIS-MPA-BASED HYPERBRANCHED COPOLYMER MICELLES IN 
BREAST CANCER CELLS 
Dendrimers and their imperfect analogues – hyperbranched polymers – are a class of 
polymers with highly branched and dendritic architecture. This unique structure leads to 
enhanced solubility and provides a large number of available surface groups that make 
dendrimers and hyperbranched polymers promising as scaffold materials for tissue 
engineering, as DDSs, and as diagnostic imaging agents. bis-MPA-based dendrimers and 
hyperbranched polymers have been investigated for use in targeted positron emission 
tomography (PET) imaging and as carriers of DOX.188,189 These polymers are 
biodegradable and display good biocompatibility towards human cancer cell lines and 
primary cells.170,190  
In this study, we focused on understanding the cellular uptake and intracellular transport 
profiles of the Boltorn-PEG system. This system is derived from hyperbranched bis-MPA 
units and PEG segments and has demonstrated promising properties as a DDS.165 We first 
synthesized the Boltorn-PEG system (H30-(PEG10k)5) from the hyperbranched polyester 
Boltorn H30 and PEG monomers as described in previous research.165 We then conjugated 
them with the organic dye fluorescein to form H30-(PEG10k)5-FL as describe by Gong et 
al.191, and the pure polymer was obtained via dialysis (10 kDa MWCO) and freeze-drying. 
The micellar NPs with an average size of 54 ± 20 nm (DLS intensity average) were formed 
by self-assembly of copolymers in PBS solution. 
In order to understand the profile of the uptake of NPs, we first investigated the possible 
factors that might influence the cellular uptake of NPs using the breast cancer cell line 
MDA-MB468. The cellular uptake of NPs was quantified by determining the normalized 
florescence intensity with respect to milligrams of cell protein.  
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For the time-dependence investigation, we incubated cells with 300 µg·mL−1 of NPs 
(equivalent concentration of 1 µM of conjugated fluorescein) for different times. We 
observed a significant internalization after 30 min indicating rapid translocation of NPs into 
cells. The half-maximal uptake was found around 0.8 h after which the uptake amount 
increased continuously. The NP concentration-related uptake was then assessed by 
incubating cells with various concentrations of NPs from 0 to 300 µg·mL−1 for 3 h. Not 
surprisingly, a concentration-dependent behavior was observed, and the internalization of 
NPs was also confirmed by confocal microscopy. For the temperature (energy)-dependence 
assessment, cells were incubated with NPs (300 µg·mL−1) for 3 h at 37 °C or 4 °C, and a 
clear reduction of uptake was observed at the lower temperature through both quantification 
analysis and confocal imaging. Furthermore, we confirmed the energy-dependent uptake of 
NPs by administering 10 mM sodium azide and 5 mM 2-deoxyglucose to cells and 
observing a significant decrease in the uptake of NPs. Serum was also found to inhibit the 
internalization of NPs compared to normal medium without serum, indicating that the 
association of serum proteins to the NPs might influence the uptake profile of the NPs. 
Second, the mechanisms of NP internalization were determined by co-localization studies 
of NPs and fluorescence-stained biomarkers of endocytic pathways. Three different 
endocytic pathways were investigated, including the clathrin-dependent (transferrin-Alexa 
647 stained), caveolae-mediated (CTB-Alexa647 labeled), and macropinocytosis-mediated 
(dextran rhodamine stained) pathways. Strong co-localization was observed between NPs 
and the clathrin-dependent pathway and the macropinocytosis-mediated pathway. An 
endocytic inhibition assay was used to confirm these results. This showed significant 
reductions of cell-associated fluorescence in cells with inhibitors of the clathrin or 
macropinocytosis pathways compared to those without any inhibitors. 
The last step was to identify the intracellular trafficking route of NPs after endocytosis. In 
order to achieve this, co-localization assessments between NPs and different fluorescence-
stained organelles, such as early endosomes (EEA1), lysosomes (lysotracker), and the 
Golgi network (TGN), were performed with confocal microscopy after 3 h administration 
of NPs to MDA-MB-468 cells. Strong co-localization signal (yellow color) was observed in 
lysosomes, while a weak correlation was found in early endosomes and the Golgi network 
suggesting that the NPs were mainly trapped in lysosomes. Combined with further positive 
results from the study of the effects of lysosomotropic agents on the uptake of NPs, we 
concluded that NPs could bypass early endosomes and the Golgi network and translocate 
into lysosomes where they can be degraded and release their cargos. 
Finally, in order to strengthen the finding of this study other cell lines including A498, 
MDA-MB-231, MCF-7, and RAW 264.7 were used to evaluate the uptake of NPs. These 
results showed very similar uptake profiles in all of these cell lines, but RAW 264.7 cells 
exhibited the highest level of NP internalization due to their phagocytic capacity. 
In summary, bis-MPA based hyperbranched NPs can be transported into cells via clathrin- 
and macropinocytosis-mediated endocytosis, and the uptake process is time, concentration, 
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and energy dependent. 
 
4.3 PAPER III. IN VITRO EVALUATION OF NON-PROTEIN ADSORBING 
BREAST CANCER THERANOSTICS BASED ON 19F-POLYMER 
CONTAINING NANOPARTICLES 
The term theranostic is derived from the combination of the words ‘therapy’ and ‘diagnostic’. 
Theranostic NPs are dual-functional nanoscale systems that can serve as diagnostic agents 
and chemotherapeutic carriers at the same time. Fluorinated polymers can serve as imaging 
contrast agents for 19F-MRI due to the high amount of fluorine atoms in the polymer. 
To this end, a library of fluorinated NPs was developed and evaluated in vitro as a potential 
theranostic system against breast cancer cells. These NPs were obtained from the self-
assembly of amphiphilic block polymers that were synthesized in a two-step strategy. In the 
first step, a number of different linear low molecular weight or low generation dendritic 
hydrophobic atom transfer radical polymerization (ATRP) initiators were synthesized via 
standard base-catalyzed esterification reactions. The second step was the polymerization of 
hydrophilic copolymers using the hydrophobic ATRP initiators from the first step and 
monomers of oligo(ethylene glycol) methyl ether methacrylate (OEGMA, average 
molecular mass (Mn) = 475) and TFEMA. The fluorine atoms (from TFEMA) were 
randomly introduced into the hydrophilic segments of the polymer in this step and 
subsequently formed either linear or star-shaped (generation zero ([G#0]), 4 arms or 16 
arms) amphiphilic polymers with different molecular weights for the hydrophilic segment. 
The structural integrity of these copolymers was subsequently confirmed by 1H-NMR and 
SEC analysis. All of the resulting copolymers demonstrated good solubility in PBS, very 
low CMCs (0.8–3.8 µg·mL−1), and the ability to self-assemble into NPs and to encapsulate 
DOX to form DOX-NPs via the two-phase emulsion method. DLS and TEM were used to 
confirm NPs/DOX-NP formation and to determine their diameters. TEM images revealed 
that NPs have circular shapes ranging in size from 7 nm to 15 nm, and this is slightly larger 
compared to the sizes of NPs in PBS determined by DLS (6–9 nm). 	  
According to DLS, the sizes of DOX-NPs increased significantly after encapsulation of 
DOX to 800–1400 nm indicating the formation of aggregates after drug loading. In order to 
eliminate aggregation, the Chol-P(OEGMA-co-MMA-co-TFEMA) NP (poly(), P(); 
cholesterol, chol; methacrylic acid, MAA) was synthesized by replacing 50% of the 
OEGMA monomers with MAA monomers to provide negative charges to the NPs. The 
sizes of these DOX-loaded NPs were successfully reduced to 40 nm. This indicates that the 
aggregation of drug-loaded NPs could be reduced by introducing negative charges into the 
hydrophilic segments of the NPs. 
Three NPs – EBiB-P(O-co-T), Chol-P(O-co-T), and [G#0]-P(O-co-T)28k – were selected for 
19F-NMR diffusion studies in PBS, complete DMEM, and plasma. The sizes of NPs (5.6–
6.3 nm) in PBS measured by 19F-NMR diffusion were very similar to the DLS results. In 
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DMEM and plasma, these sizes were slightly smaller than in PBS. This shrinking in size 
might be caused by the reduction of polymer solubility in the complex medium. However, 
there was no significant size increase after NPs were placed in a protein-rich environment, 
and this suggests that these NPs can avoid protein absorption and that the poly(OEGMA-
co-TFEMA) provides a stealthy corona on the NPs. 
To further evaluate these NPs as a DDS, their loading capacities and release profiles were 
also investigated. The loading efficiencies of the NPs from this library were generally 
similar, from 70% to 89%. In general, [G#2]-polymers displayed a higher loading capacity 
than [G#0]-polymers suggesting that larger hydrophobic cores have higher loading 
capacities. Interestingly, one of the linear core NPs, Chol-P(O-co-T) exhibited a similar 
loading efficiency(ca. 88%) compared to [G#2]-P(O-co-T)23k (ca. 89%), indicating that 
cholesterol is a promising candidate for constructing hydrophobic cores. For the in vitro 
drug release study, it was not surprising to find that star-like and larger hydrophobic cores 
displayed slower release rates and that Chol-P(O-co-T) showed a similar release profile 
compared to the [G#2]-NPs. This confirmed that [G#2]-polymers and cholesterol cores are 
suitable for drug delivery applications. 
The efficacy and toxicity of DOX-NPs are other key properties for DDS evaluations. 
Cellular viability was determined by measuring mitochondrial function in cells with an 
MTT assay. The results revealed that pure NPs (0.01–500 µg·mL−1) without DOX 
encapsulation were non-toxic to three breast cancer cell lines (MCF-7, MDA-MB-231, and 
MDA-MB-468) and one monocyte cell line (RAW 264.7). However, when loaded with 
DOX these NPs exhibited significant toxic effects (at 10 µg·mL−1) towards these cell lines. 
They all had either similar or lower IC50 compared to free DOX suggesting that all of these 
materials have good drug-carrying properties. Apoptosis assays determined by 
fluorescence-activated cell sorting (FACS) also revealed that DOX-NPs could induce 
apoptosis in these cell lines in a similar manner as free DOX after 24 h and 48 h.  
The uptake of the NPs was also confirmed by FACS showing increased FITC signals from 
two fluorescent labeled copolymer FITC-Chol-P(O-co-T)15k and FITC-[G#0]-P(O-co-
T)28k.To further track the intracellular locations of NPs, MDA-MB-231 and RAW 264.7 
cells were incubated with FITC-[G#0]-P(O-co-T)28k NPs for designated time periods and 
observed with a confocal microscope. The FITC-NPs were mainly observed in the 
cytoplasm and closely surrounding the nuclei, unlike DOX or DOX released from NPs that 
was mainly found in the nuclei. This result confirmed the uptake of the NPs and suggested 
that NPs cannot penetrate the nuclear membrane. Moreover, in order to analyze the 
intracellular distribution of DOX release from NPs, MDA-MB-231 and RAW 264.7 cells 
were treated with 5 µg·mL−1 equivalent free DOX (control), DOX-[G#0]-P(O-co-T)28k, or 
DOX-Chol-P(O-co-T) NPs for different time periods. A rapid uptake (4 h) of free DOX and 
DOX release from NPs was observed in these cells, and the DOX tended to concentrate in 
the nuclei. In addition, the signal of DOX release from the NPs became stronger from 4 h to 
48 h incubation indicating that the NPs could continuously release encapsulated DOX 
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intracellularly. 
The imaging function of the fluorinated NPs was analyzed in vitro by 19F-MRI. The strong 
MRI phantoms of NPs (190–970 µM in PBS, equivalent fluorine concentrations 23–56 
mM) can be rapidly achieved within 10 min scanning time. This indicated that excellent 
MRI signals were introduced by fluorinating the NPs and demonstrates that they are 
promising candidates for 19F-MRI imaging. 
 
4.4 PAPER IV. TOWARD UNIMOLECULAR MICELLES WITH TUNABLE 
DIMENSIONS USING HYPERBRANCED DENDRITIC-LINEAR POLYMERS 
Unimolecular micelles were developed from PEGylated hyperbranched dendritic-linear 
polymers (HBDLPs) via a versatile two-step procedure and further evaluated as a potential 
DDS. The first step was to synthesize hydrophobic hyperbranched macroinitiators (HBMI) 
from self-condensing vinyl (co) polymerization (SCV(C)P) utilizing ATRP. The second 
step was to produce hydrophilic polymers by adding hydrophilic segments to the 
hydrophobic HBMI through chain extension. 
In the first step, two HBMIs (full name HBMI(TBBPE-co-BBEMA-co-HA)) were 
synthesized from the inimer 2-(2- bromoisobutyryloxy)ethyl methacrylate (BBEMA), the 
comonomer hexyl acrylate (HA), and 1,1,1-tris(4-(2-bromoisobutyryloxy)phenyl)-ethane 
(TBBPE) by employing SCV(C)P-ATRP with different ratios of these components. The 
resulting HBMI-1 and HBMI-2 were further characterized by 1H NMR (CDCL3) and SEC. 
The average polymer ratio of TBBPE:BBEMA:HA was calculated as 1:12:37 for HBMI-1 
and 1:51:295 for HBMI-2. Further evaluation of the HBMIs by SEC with DMF as the 
mobile phase showed different elution times indicating a clear difference in hydrodynamic 
volume between HBMI-1 and HBMI-2 whose molecular weights were determined to be 
3600 g·mol−1 and 6100 g·mol−1, respectively. In addition, the estimated average degrees of 
polymerization of BBEMA and HA were calculated from 1H NMR as 49 for HBMI-1 and 
346 for HBMI-2. The average number of Br per molecule was determined as 15 and 54 for 
HBMI-1 and HBMI-2, respectively, by assuming one TBBPE-moiety per HBMI and high 
end-group fidelity. 
In the second step, a library of amphiphilic HBDLPs (HBDLPs 1–5) was synthesized by 
chain-extending HBMIs with different lengths of P(OEGMA) segments via ATRP. In order 
to demonstrate that additional functionality such as imaging properties could also be 
achieved with this method, an additional HBDLP was synthesized by chain-extension of 
HBMI-2 with P(OEGMA), the fluorine-containing copolymer TFEMA, and t-BMA 
followed by the removal of tert-butyl groups to form MAA residues. Such copolymers have 
previously been reported to be able to generate detectable 19F-MRI signals for imaging 
applications. These HBMIs-P(OEGMA)x polymers (x = 103 kDa, 473 kDa, 230 kDa, 
410000 kDa, 605000 kDa from HBDLP-1 to HBDLP-25) and HBMI-P(OEGMA-co-
TFEMA-co-MAA)287k were further characterized using DLS, 1H-NMR self-diffusion, and 
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SEC-MALLS. SEC-MALLS determined the molecular weight of the HBDLPs to be 100–
600 kg·mol−1. 
HBDLP NPs were obtained by self-assembly of materials in PBS solution following the 
evaporation of the organic solvent CH2Cl2. The mean diameters (z-average) of NPs 
determined by DLS were 17–39 nm. The other three average parameters (number, volume, 
and intensity weighted diameter from DLS) were also in a similar range as the z-average. 
The sizes of NPs were also measured by NMR diffusion and calculated by the Stokes-
Einstein equation. The average diameters determined by this method were 10–24 nm. 
Despite the different diameters determined with the two methods, both DLS and NMR 
diffusion measurements revealed an increasing correlation between diameter and 
P(OEGMA) extension indicating that the HBDLPs had tunable sizes using this synthesis 
strategy. TEM images further confirmed the size of NPs being in the range of 10–20 nm 
and showed that the NPs had the expected core-shell morphology. The SEC-MALLS 
measurements showed that the NPs had high molecular weight range (100–600 kg·mol−1) 
as polymers, and this indicated that these NPs had unimolecular weights. 
To evaluate these unimolecular NPs as a DDS, we first loaded DOX into the NPs via the 
two-phase emulsion method and measured in vitro drug release in PBS solution. All of the 
NPs demonstrated the ability to encapsulate the drug and had slower release profiles 
compared to free DOX in PBS (60% of the drug was released from the NPs within 10 h). 
Furthermore, MTT assays were carried out in three breast cancer cell lines and one mouse 
macrophage cell line to evaluate the toxicity of the materials. No obvious toxicity was 
found for NPs formed from HBDLP1–5 in the concentration range of 0.1–100 µg·mL−1. 
However, a reduction in mitochondrial function was observed in cells incubated with 100 
µg·mL−1 of the HBDLP6 NP, and this might be due to incomplete removal of copper during 
the synthesis. DOX-NPs demonstrated a dose-dependent efficacy in reduction of 
mitochondrial function in MDA-MB-468 cells after 48 h suggesting that the NPs could 
deliver DOX into cancer cells. This was further confirmed by localization studies with 
confocal microscopy showing time-dependent accumulation of DOX released from NPs in 
and around the nuclei. 
In summary, high molecular weight HBDLPs could be produced via SCV(C)P-ATRP. 
They can form unimolecular micelles and are promising in drug delivery applications.  
 
4.5 PAPER V. HISTAMINE-FUNCTIONALIZED COPOLYMER MICELLES AS A 
DRUG DELIVERY SYSTEM IN 2D AND 3D MODELS OF BREAST CANCER 
Polymer-based NPs have been used as DDSs in anticancer research for the last decade. One 
issue to achieving effective drug delivery with NPs is to overcome endosomal/lysosomal 
entrapment so that the drugs can be transported to their targets. pH-responsive NPs have 
been developed in order to achieve endo-lysosomal escape due to the ‘proton sponge’ effect 
caused by the charged polymer under acidic conditions. 
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Based on this idea, a library of polymer micelles was synthesized from poly(allyl glycidyl 
ether)-b-poly(ethylene oxide) (PAGE-b-PEO) followed by the functionalization of histamine 
and octane or benzyl groups through UV-initiated thiol-ene click chemistry to obtain the pH-
sensitive property. The resulting polymers were divided into four groups based on their 
chemical modifications and molecular weight, including the low PXGE MW and low PEO 
MW group (LL); the low PXGE MW and high PEO MW group (LH); the high PXGE MW 
and high PEO MW group (HH); and the benzyl-containing group (B). The X in PXGE 
refers to allyl (A), octyl (O), or histamine (H). The chemical characteristics and structures of 
these copolymers were further confirmed by SEC and 1H-NMR (for details, see paper V). 
NPs were formed through self-assembly of polymers in aqueous solution, and the DOX-NPs 
were obtained by the two-phase emulsion method. The NPs and DOX-NPs were 
characterized by DLS and TEM to determine their size and morphology. The sizes of NPs 
measured by DLS (number mean) were in the range of 16–59 nm, and this was larger 
compared to the diameter determined by TEM (6–20 nm). Moreover, diameter expansion of 
NPs after DOX encapsulation was observed as well as some aggregations. Spherical 
morphology was observed for NPs and DOX-NPs in the TEM images, and the low CMC 
(below 10 µg·mL−1) suggested that these NPs could be suitable for in vivo drug delivery. 
In the next step, we evaluated the drug loading efficiency and release profile of these DOX-
NPs to explore the effect of histamine modification. Similar drug loading efficiencies of 15% 
to 30% (w/w) were found among most of these DOX-NPs. A lower efficiency of 12% was 
seen for HH3, and higher efficiencies of 36% and 44% were observed for LH2 and B2, 
respectively. In vitro drug release was tested in buffer solution at both pH 6.0 and pH 7.4. 
Unfortunately, no obvious difference in drug release rate was found for the same DOX-NPs 
at the two pHs. However, DOX-NPs with 50% histamine functionalization (DOX-LL3, 
DOX-LH3, DOX-HH2) displayed slower drug release rates at both pHs compared to other 
materials from the same group, suggesting that the overall structures of these NPs could be 
the reason of the slower release. 
Another critical issue in DDS evaluation was the toxicity of the materials and the efficacy of 
DOX-NPs. To this end, 2D (MCF-7, MDA-MB-468 and MDA-MB-231) and 3D (MDA-
MB-231) cell cultures of breast cancer cells were established and used in toxicity evaluations. 
None of these NPs demonstrated toxic effects against the tested cell lines in either the 2D or 
3D cultures. However, the MTT assays in the 2D cell culture showed reduction of 
mitochondrial function induced by DOX-NPs compared to free drug over short treatment 
periods of 12–24 h. DOX-LL3 (50% histamine, low molecular weight group) displayed the 
strongest toxicity compared to other DOX-NPs from the same group after treatment for 72 h. 
Apoptosis assays with FACS revealed that DOX-NPs could induce more late apoptosis than 
free DOX after 72 h treatment. Histamine-containing NPs also demonstrated enhanced drug 
efficacy in 3D cultures according to ATP luminance assays and the presence of broken 
spheroids.  
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In order to determine the mechanism behind the enhanced efficacy of DOX-NPs compared to 
free drug in cancer cell treatments, confocal microscopy was used to track the distribution of 
DOX/DOX-NPs in cell cultures. Co-localization analysis of DOX-LL3 revealed relatively 
strong co-localization not only in lysosomes but also in nuclei and mitochondria, indicating 
partial endo-lysosomal escape. To better compare the drug distribution between free DOX 
and DOX-NPs in various cellular locations, a heat map was made based on the calculation of 
the co-localization parameters. The map showed enhanced residence of DOX-LL3 in the 
mitochondria and reduced drug signal in lysosomes compared to free DOX. This further 
confirmed that DOX-LL3 was able to partly escape endo-lysosomal entrapment and to 
transport DOX into the nuclei and mitochondria. To further investigate the mitochondria 
targeting property of the NPs, another heat map was produced for mitochondria co-
localizations of three NP groups in three breast cancer cell lines. The map revealed that NPs 
with 50% histamine functionalization (LL3, LH3, and HH2) tended to have stronger signals 
compared to DOX and other NPs. We also conducted a co-localization study in 3D spheroids, 
and the result was consistent with previous results showing that 50% histamine-modified 
DOX-NPs, in particularly the ones from the low molecular weight group (DOX-LL3), 
displayed the lowest co-localization in lysosomes indicating endo-lysosomal escape. 
Based on all of these results, we conclude that histamine functionalization enables polymer 
NPs to escape from endo/lysosomes and that carefully adjusting the chemical ratio of the 
modification improves drug delivery efficacy and drug distribution. 
4.6 PAPER VI. A MULTI-FUNCTIONAL NANOPARTICLE SYSTEM BASED ON 
A SMALL HUMAN PROTEIN 
In the first part of this work, we intended to demonstrate the formation of saposin-
lipoprotein (salipro) NPs through incubation of saposin A together with lipids such as 
phosphatidylcholine, phosphatidylglycerol, and phosphatidylserine (PS) in solution at pH 
7.4. Successful generation of salipro-NPs was confirmed by SEC analysis showing a 
significant peak shift of the saposin A retention time after incorporation with lipids. The 
same method was used to generate a fluorescent salipro-NP by incorporating PS labeled 
with 7-nitro-2-1,3-benzoxadiazol-4-yl (NBD). The consistency between the protein 
absorption peak (280 nm) and the fluorescence absorption peak (470 nm) observed by SEC 
proved the formation of salipro-NBD-PS NPs. The homogeneity of the NPs was confirmed 
by gel filtration, DLS, and negative-stain electron microscopy (EM) showing 95% 
homogeneity and an average NP size of 6 nm. A high degree of thermostability was also 
confirmed by SEC analysis after repeated freeze-thaw cycles. 
Satisfied that we had successfully formed salipro-NPs, several hydrophobic drugs were 
added during the generation of the NPs to evaluate the NPs’ ability to carry drugs. 
Curcumin, daunorubicin, and mitoxantrone were selected because of their intrinsic UV-
absorbance characteristics. Successful incorporation of these drugs was confirmed with 
SEC by monitoring the absorption at 280 nm (protein), 420 nm (curcumin), 480 nm 
(daunorubicin), and 655 nm (mitoxantrone) separately. A positive thermal responsive 
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behavior in drug encapsulation was identified by comparing the daunorubicin loading 
efficiency at 37 °C, 50 °C, and 65 °C. The maximal incorporation of daunorubicin was 
achieved at 65 °C, and about 95% of the drug was loaded. A pH sensitive property of 
salipro-NPs was also revealed by the degradation of the NPs at pH 4.75. All of these results 
implied that salipro-NP might serve as a DDS. 
To further evaluate salipro-NP as a DDS, several in vitro experiments were performed. 
First, we tested whether salipro-NPs can interact with cancer cells. Breast cancer cells 
(MDA-MB-468) were incubated with fluorescently labeled salipro-NBD-PS NPs at 
designated concentrations and times. Both time and concentration-dependent fluorescent 
signals were observed. Further co-localization revealed that the NPs were primarily located 
in the membrane. In the second step, the release profile of daunorubicin from NPs was 
investigated in PBS solution. A slow and linear release rate was observed, and 20% of the 
drug was released from the NPs over 24 h. This was much slower compared to unloaded 
drug that had 100% release from a dialysis unit within 12 h. At 96 h, 70% of the 
daunorubicin had been released. Further investigation of intracellular drug distribution 
revealed a time-dependent release of daunorubicin from salipro-NPs, and daunorubicin was 
observed throughout the cytoplasm after 72 h incubation. This is quite different compared 
to free drug-treated cells in which daunorubicin only concentrated in the nuclei after 72 h. 
Because salipro-NBD-PS NPs were only found in the cell membrane, this suggested that 
daunorubicin-carrying NPs could indeed release their cargos intracellularly.  
To expand the application of salipro-NPs, we explored the possibility encapsulating 
insoluble membrane proteins into the salipro-NPs. Both prokaryotic (bacterial peptide 
transporters POT1 and POT2) and eukaryotic (the human membrane protein synaptophysin, 
SYP) were incorporated as confirmed by SEC. The 3D structure of salipro-POT1 was 
reconstructed via data collected from negative-stain EM. The analysis demonstrated that 
salipro-NPs could be assembled flexibly due to the adaption of the saposin A-lipid system 
to the size of the incorporated molecules. Satisfied with the proven concept, salipro-NPs 
were further used to reconstitute HIV-1 spike proteins and to maintain their ability to 
produce potential vaccine antigens. Salipro-HIV-spikes were formed by incubating saposin 
A, detergent, and HIV-1 spike proteins in the viral membrane followed by rapid removal of 
the detergent with spin desalting columns. Blue native polyacrylamide gel electrophoresis 
(BN-PAGE) analysis confirmed the formation of the desired NPs, and highly specific lectin 
affinity chromatography was used to further purify the NPs. The final purity of the salipro-
HIV-spikes was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and visualized by negative-stain EM. The function of salipro-HIV-spikes was 
further determined by the binding of PG16 antibody. 
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5 GENERAL DISCUSSION 
 
5.1 DRUG LOADING AND RELEASE FOR POLYMER NPS 
In papers I and III–V, drug loading was mainly achieved via a two-phase emulsion method 
based on the hydrophobic entrapment of the drugs.192,193 The loading efficiency was in the 
middle range compared to previously published reports with the same method.165,168 The 
fundamental advantage of this method is the ability to rapidly screen NPs as a DDS. The in 
vitro release model established in these papers cannot represent the complex situation in vivo, 
but, it can provide a convenient way to compare the release profiles between different 
polymer NPs. 
In order to achieve good loading, a polymer NP has to have a well-designed hydrophobic 
core. For example, in paper III, we evaluated different types and shapes of hydrophobic 
cores and found that the star-like and cholesterol cores are more suitable for drug delivery 
applications because they have slower release rates. Therefore, the drug release kinetics can 
be tailored by designing different chemical compositions that control the hydrophobicity of 
the DDS. However, in paper I burst drug release was observed for both DL and HBDL NPs, 
suggesting that their cores were not sufficiently dense or hydrophobic to keep the drug inside.  
One potential way to prevent premature drug release is to covalently link the drug to the 
polymers.194 Such linkages eliminate loosely attached drugs and thus avoid rapid drug 
release.195 Moreover, introducing chemical bonds that are sensitive to external stimuli might 
allow the drugs to be released from the NPs only when the stimuli are encountered.196 pH-
responsive linkers are commonly utilized for such purposes.197 These bonds will break when 
the NP encounters acidic environments such as endo-lysosomes and the microenvironment of 
solid tumors, and the NP will then release its cargo.198,199 In paper V, histamine-containing 
NPs were designed to have pH-responsive drug release. Although no significant differences 
in drug release were observed between pH 6 and pH 7, NPs with 50% histamine still 
displayed good properties as a DDS. Considering the good pH responsive behavior seen for a 
set of similar copolymers,200 we believe that the pH responsiveness might be hampered by the 
hydrophobicity of the histamine linker. 
Another issue regarding drug encapsulation and release is the need to reduce aggregation 
after drug loading. Aggregation might occur if DOX is not perfectly loaded into the core. To 
solve this issue, a proper hydrophilic layer is critical. The most commonly used hydrophilic 
modification is PEGylation.45,46,201,202 OEGMA is a good alternative to PEG203-205 and was 
utilized in papers III and IV. However, hydrophilic shielding alone might not solve the 
problem completely, and aggregations could still be found for OEGMA-modified NPs in 
paper III. To solve this problem, we introduced negative charges to the system with a 
cholesterol core and observed a significant reduction in aggregation.  
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5.2 HYPERBRANCHED POLYMERS VS. DENDRIMERS AND DENDRONS 
The dendritic polymer family includes dendrimers and dendrons, dendrigrafts, and 
hyperbranched polymers.206 Among these, hyperbranched polymers, dendrimers, and 
dendrons are used in biomedical applications such as drug delivery.140 But which type is 
more suitable for use in real medical application in the future?  
The bis-MPA-based DL hybrid system was first introduced in the early 1990s by Frechet et 
al.207 These bis-MPA-based polymers are suitable for biomedical use because of their non-
toxic nature and their biodegradable properties.164,190 In paper I, HBDLs were 
comprehensively compared to their dendron analogs and to DL polymers as a DDS with 
regard to synthesis, loading capacity, release profile, and efficacy. For the synthesis process, 
HBDL was produced by a one-step Fisher esterification reaction from the mixture of bis-
MPA and PEG monomers. This was much more convenient compared to the synthesis of 
dendrons from multiple steps,187 and the HBDLs could be produced on a 50-gram scale. DL 
micelles expanded less compared to HBDL micelles after encapsulating drugs according to 
DLS data, and their loading efficiencies were slightly higher implying that DL micelles 
have better performance regarding drug loading and reducing aggregation after DOX 
loading. However, this better performance in drug loading did not lead to better release 
properties. Both DL and HBDL with (pseudo) G3 and G4 cores showed burst release of the 
drug, and about 80% of the DOX was released within 12 h. HBDL micelles demonstrated 
slightly slower release than DL micelles. The release rates of these four micelles were much 
faster compared to bis-MPA dendrimers with a G5 core, which showed less than 40% 
release after 24 h.208 This suggests that the hydrophobic cores of current DL or HBDL 
systems are not sufficient to keep the drug stably encapsulated. In future applications, the 
hydrophobic core should be expanded. Further comparisons regarding toxicity and efficacy 
of both systems revealed that they were all non-toxic as pure micelles but demonstrated 
improved efficacy of loaded DOX. In particular, DOX-HBDLs and DOX-DL with a G4 
core displayed 20% greater toxicity to MDA-MB-231 breast cancer cells compared to free 
DOX. Considering all these aspects, HBDL is a promising alternative to its dendron-based 
analog because they both have similar properties as a DDS but HBDLs are much easier to 
produce.  
Another consideration in the comparison of hyperbranched polymers vs. dendrimers and 
dendrons is the intrinsic limitation of micelles formed by amphiphilic copolymers. The 
micellar structure of an amphiphilic copolymer such as HBDL or DL can only be 
maintained above the CMC.209,210 In antitumor applications, micelles are usually 
administered intravenously and this leads to the dilution of micelles and potential loss of 
their structural integrity.79 However, because dendrimers are unimolecular macromolecules 
they do not have a CMC and are thus considered to be interesting candidates for theranostic 
platforms.211,212 Unimolecular micelles can also be produced from hydrophobic dendritic 
cores that are covalently linked to hydrophilic polymers such as PEG.136,202,213-215 In paper 
IV, a library of unimolecular micelles was successfully developed from HBDL polymers 
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that were synthesized from hyperbranched macro-initiators (HBMI) following chain 
extension using hydrophilic P(OEGMA). P(OEGMA) has been used as a good substitute 
for PEG.216,217 These micelles are nontoxic and are capable of encapsulating DOX and 
delivering it into breast cancer cells with high efficacy. The release profile of these 
unimolecular micelles was not tailored very well, and this is a common issue for all 
unimolecular systems, including dendrimers, that use physical drug encapsulation.218 This 
can be solved by covalently conjugating drugs to the polymers.218 In addition, the 
fluorinated polymer TEFMA was added to the hydrophilic compartments, and this could 
theoretically provide the micelles with an MRI contrast property and allow them to be used 
as a theranostic platform. Considering the simple synthesis process compared to 
dendrimers, hyperbranched unimolecular micelles are indeed a promising approach to 
developing scalable theranostic systems. 
 
5.3 INTERNALIZATION AND INTRACELLULAR DISTRIBUTION OF POLYMER 
NPS 
5.3.1 Cellular uptake mechanisms of NPs 
The primary mechanisms of endocytosis are phagocytosis, macropinocytosis, caveolae-
assisted endocytosis, clathrin-mediated endocytosis, as well as clathrin-independent and 
caveolin-independent endocytosis.10,142 Phagocytosis is usually found in specialized cells 
such as macrophages when they eliminate exogenous substances.142,219 The other mechanisms 
are commonly investigated regarding cellular uptake of NPs (Figure 4).220 In paper II, a 
comprehensive investigation into the internalization of bis-MPA-based hyperbranched 
polymer micelles was performed on the breast cancer cell line MDA-MB-231. The uptake 
procedure was found to be dependent on time, concentration, and temperature. Further 
confocal microscope observations and endocytic inhibition assays revealed that NPs were 
internalized through both macropinocytosis and clathrin-mediated endocytosis rather than 
caveolae-assisted endocytosis. Particles that are internalized via caveolae-assisted 
endocytosis are typically around 60 nm,142,219 which is much smaller than the size of the bis-
MPA-based NP used in the paper (average 110 nm), and this explains why caveolae-assisted 
endocytosis was not a major pathway for these NPs. Clathrin-mediated uptake is the main 
mechanism of cellular uptake of macromolecules that have a size around 120 nm,10,140 and 
this is consistent with our observations. Macropinocytosis is a nonspecific uptake pathway for 
the internalization of large (>1 µm) and irregularly shaped molecules.10,220 Although the size 
of bis-MPA-based hyperbranched NPs in this study (110 nm) was smaller than 1 µm, we still 
observed the uptake of NPs through this pathway. This might be related to the irregular shape 
of hyperbranched NPs. Furthermore, intracellular tracking of NPs in early endosomes, 
lysosomes, and the Golgi network revealed that NPs were mainly found in lysosomes, which 
is the typical fate of macromolecules internalized via clathrin-mediated endocytosis.142  
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Figure 4. The main mechanisms of cellular uptake of NPs. A) Macropinocytosis, B) 
clathrin-mediated endocytosis, C) caveolae-mediated endocytosis, D) clathrin-independent 
and caveolin-independent endocytosis. (The image is modified from DeSimone et al.10) 
 
5.3.2 Endo-lysosomal escape 
Polymer-based NPs have been used as DDSs in anticancer research for the last decade, and 
one important problem that needs to be solved is how to enable NPs to overcome 
endosomal/lysosomal entrapment so that they can transport their drugs to their targets.221-224 
Endo-lysosomal entrapment is the fate of most exogenous macromolecules, and the acidic 
environment in endo-lysosomes might lead to the degradation of therapeutic 
agents.10,140,220,225,226 One solution to avoiding endo-lysosomal entrapment is to design NPs 
that can be taken up by caveolae-assisted endocytosis or macropinocytosis.142 Another option 
is to design NPs with endo-lysosomal escape properties such as a pH responsive behavior that 
allows NPs to become positively charged in the acidic environment resulting in the “proton 
sponge effect” to escape entrapment.135,221,227,228 In paper V, a library of NPs with 
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functionalized histamine copolymers was produced, and these NPs displayed some ability to 
escape from endo-lysosomes. This system was developed based on our previous research in 
which a histamine-functionalized system was reported to show conformation changes in 
acidic pH due to the positive charges.200 The capability of endo-lysosomal escape resulting 
from the introduction of histamine modification was related to the chemical composition of 
the copolymer. NPs with 50% histamine functionalized in their hydrophobic compartment 
showed the greatest ability to escape the endo-lysosomes and deliver their drug into the 
mitochondria and nuclei. Due to its good biocompatibility and pKa in a physiologically 
relevant pH range (pH 6.0–7.4), histamine has been used to modify other polymer systems 
for siRNA and drug delivery as reported by Wooley et al. and Liu et al., respectively. 229,230 
 
5.4 THERANOSTIC SYSTEMS – FOCUSING ON MRI DETECTION 
As mentioned in the introduction, there are various theranostic systems currently being 
developed for antitumor applications. Such systems can provide both imaging information 
about the tumor and therapeutic efficacy during chemotherapeutic therapy.231,232 Unlike PET, 
SPECT, and CT, MRI detection does not rely on radioactive agents, and this makes it suitable 
for theranostic applications that might require multiple administrations. Several systems have 
been demonstrated for improving MRI contrast, including lipid based,233 silica based234,235, 
and metal based (such as gold NPs236 and SPION129) systems, as well as the fluorinated 
polymer-based system described in paper III. However, silica and lipid-based systems need 
to introduce gadolinium or other metal-based NPs to serve as contrast agents.233,234,237 Most 
metal-based NPs require further coating of lipids or polymers to achieve better 
biocompatibility and longer blood circulation times.238,239 In addition, these contrast agents 
suffer from some disadvantages such as long acquisition time, high background signal from 
blood and tissue, and toxicity issues caused by the high concentrations of the contrast agents 
required for 1H-MRI.84,240,241 On the contrary, fluorinated polymer-based systems do not 
depend on other magnetic NPs. They can generate a strong 19F signal even though the 
sensitivity of 19F is 83% that of 1H.84 Moreover 19F is the only natural isotope of fluorine, and 
because it is not present in most tissues this leads to low background signals in 19F-MRI.84 
Based on these properties, fluorinated polymers were investigated as potential contrast agents 
for 19F-MRI.84,242,243 The NPs that we developed were able to encapsulate drugs, and these 
could be delivered in a controllable manner by modifying the hydrophobic cores. These same 
NPs could generate very strong signal for 19F-MRI in vitro when they incorporated the 
fluorine-containing polymer TEFMA. However, our current systems suffer from two 
limitations. First, because ours is a copolymer system, it has a CMC issue that might limit its 
application in vivo. To solve this issue, we built a library of unimolecular polymers in paper 
IV that do not have a CMC problem. We then added TEFMA to one of these polymer 
systems and obtained unimolecular micelles with a fluorinated component. Another 
limitation for the theranostic systems in paper III is that they lack targeting molecules, which 
limits the concentration that can be achieved at the site of the tumor. Therefore, future studies 
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should add a suitable targeting molecule to try to further improve the accumulation of 
fluorinated NPs in the tumor area in vivo. This approach is based on the work of Thurecht et 
al. who attached folic acid to their fluorinated polymer NPs and achieved 19F-MRI detection 
of tumors in vivo. 244  
 
5.5 COMPARISON BETWEEN SALIPRO-NPS AND POLYMER-BASED NPS  
The salipro-NP described in paper VI is a good example of harnessing biomimic properties 
for nanomedicine applications. Compared to the polymer NPs in this thesis, salipro-lipid NPs 
demonstrated the highest loading capacity, 95%. The drug encapsulation procedure was very 
simple, and only entailed incubating hydrophobic lipids and daunorubicin together. 
Moreover, they showed a slower drug release rate than polymer NPs over a period of 72 h. 
The slow drug release will enable NPs to better retain their cargo while in circulation and 
then release it at the tumor site due to EPR effects. However, considering the size of salipro-
lipid NPs, which was around 6 nm, further polymer modification might be required for drug 
delivery applications.  
The uptake of salipro-lipid NPs was also very different compared to polymer NPs. Due to 
their similar composition as the cellular membrane, salipro-lipid NPs tend to fuse with the 
cell membrane and become trapped there according to the confocal microscopy data. Thus 
they cannot mediate daunorubicin accumulation in the nuclei as rapidly as histamine-
containing NPs, but they can release drugs gradually into the cells and finally achieve 
distribution in the whole cell. This is consistent with their release profile in vitro.  
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6 CONCLUSIONS 
 
Paper I 
• Two novel HBDL and their perfect DL analogues were synthesized using bis-MPA 
and PEG as building materials.  
• One-step Fisher esterification reactions allowed production of HBDL on a larger scale 
than DL.  
• DL showed less aggregation than HBDL after drug loading. 
• Both HBDL and DL had burst-like drug release within 12 h indicating the insufficient 
size of their hydrophobic cores. 
• All of the materials were non-toxic to the breast cancer cell line MDA-MB-231, and 
drug-loaded HBDL tended to have stronger efficacy compared to DL. 
• Based on all of the results, we conclude that HBDL can serve as an alterative to DL in 
biomedical applications, but further refinement is needed for use as a DDS. 
Paper II 
• A set of bis-MPA-based polymer micelles was synthesized from hyperbranched 
polyester Boltorn and PEG and labeled with fluorescein. 
• bis-MPA-based polymer micelles could be transported into breast cancer cells (MDA-
MB-468) via clathrin- and macropinocytosis-mediated endocytosis.  
• The uptake process was time, concentration, and energy dependent. 
Paper III 
• Eight fluorinated polymer NPs with different compositions were synthesized via 
ATRP. 
• The NPs could form by self-assembly of both linear and star-shaped block 
copolymers. 
• These NPs could encapsulate and release DOX, and the drug release kinetics could be 
tailored by the architecture of the hydrophobic cores. 
• All materials were non-toxic to the tested cell lines, but DOX-NPs could induce 
mitochondrial function loss and significant apoptosis in breast cancer cells  
• The in vitro MRI measurement demonstrated that the NPs could generate detectable 
MRI signals.  
• Taken together, these results indicate that these fluorinated polymers are promising in 
theranostic applications. 
Paper IV 
• Unimolecular micelle NPs were successfully synthesized via a versatile two-step 
procedure from a library of PEGylated HBDLPs. 
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• HBDLPs formed predominantly stable and spherical NPs, and the NP dimensions 
could be tailored by the polymer architecture and hydrophobic/hydrophilic ratio. 
• The unimolecular NPs were non-toxic to three breast cancer cell lines (MDA-MB-
231, MDA-MB-468, and MCF-7) and one monocyte cell line (RAW 264.7). 
• The NPs were able to incorporate and release DOX, and the NPs showed good 
efficacy against the cancer cells and could be internalized into MDA-MB-468 cells. 
Paper V 
• A library of histamine-functionalized copolymer micelles was synthesized from 
PAGE-b-PEO via UV-initiated thiol-ene click chemistry. 
• The subsequent materials were non-toxic and could self-assemble into polymer 
micelles to deliver DOX, and they exhibited a higher efficacy in reducing 
mitochondria function compared to free DOX. 
• The histamine modification did not introduce a strong pH-responsive property to the 
micelles, but the 50% histamine-modified NPs tended to have a slower drug release 
rate.  
• DOX-NPs with 50% and 100% histamine modification exhibited significantly 
stronger efficacy in 3D models compared to free DOX.  
• Histamine-functionalized micelles, in particular the ones with 50% modification in 
the low molecular weight group, could partly escape from endo-lysosomes and 
relocate in the mitochondria. 
Paper VI 
• A stable NP system was successfully developed by enclosing the small human protein 
saposin A within a hydrophobic lipid core.  
• The salipro-NPs could incorporate a variety of lipids, membrane proteins 
(prokaryotic/eukaryotic), viral antigens, and hydrophobic drugs. 
• The salipro-NPs could interact with the cell membrane, and the daunorubicin-
encapsulated salipro-NPs could release the drug into breast cancer cells suggesting 
that such an NP system can be potentially used as a DDS. 
• The HIV-1 spike protein (antigen) was also reconstituted into salipro-NPs and 
maintained in a native and functional state, and this suggests the possibility for the 
generation of NP-based vaccines for unstable antigens. 
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7 FUTURE PERSPECTIVES 
The studies summarized in this thesis were mainly focused on screening suitable NPs as DDS 
platforms for breast cancer therapy. These NPs, especially the polymer-based NPs, are 
theoretically expected to be able to delivery drugs in vivo due to the EPR effect, but we have 
not yet tested any of these systems in vivo. For future studies, the following issues should be 
explored in order to optimize these compounds as a DDS.  
We should introduce targeting molecules such as peptides, folic acid, transferrin, antibodies, 
or aptamers into the polymer systems. This is especially crucial in the case of developing 
theranostic systems. Our current theranostic systems have shown significant efficacy in vitro, 
but the required concentrations were high at around 10 mg·mL−1. Such high concentrations 
cannot be reached in vivo with a single injection; therefore, we need to find a suitable way to 
achieve active targeting to further increase the local concentration of the NPs at the tumor 
site.  
Furthermore, drugs should be covalently linked to our promising polymer NPs to improve the 
loading capacity and to introduce a triggered drug release system. Moreover, we should 
consider dual drug delivery or co-delivery of drugs and siRNA to further improve the 
therapeutic efficacy via synergistic effects.  
With the emergence of novel gene editing tools such as the CRISPR/Cas-9 system, further 
development of NPs as a delivery system should focus on assisting the somatic delivery of 
gene editing system to provide better therapies for various diseases.  
In addition, the long-term toxicity issue of polymer NPs should be investigated in detail to 
make sure patients do not suffer additional harm when such constructs progress to clinical 
testing. 
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